Ceremonial melon

9 January 2017 By Robert Cyran

The $34 bln drug maker is the latest to pay over the odds. It’s shelling out a 75 pct premium for Ariad, a biotech with a middling cancer drug. Takeda needs to refill its pipeline as patents on existing treatments expire, but the $5.2 bln purchase price looks too generous.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)